156 filings
Page 2 of 8
6-K
8rwo02icvb6go4
1 Aug 23
CureVac Announces Dosing of First Participant in Phase 2 Study of Modified COVID-19 mRNA Vaccine Candidates Developed in Collaboration with GSK
4:15pm
6-K
9ek5wd33
14 Jul 23
CureVac Announces Update to the Management Team
4:01pm
6-K
lpzrbyar7my2
13 Jul 23
CureVac Strengthens Ongoing Patent Litigations Bringing Additional Cases Under New Intellectual Property Rights
4:01pm
6-K
fc1jvnrg
22 Jun 23
Current report (foreign)
4:01pm
6-K
30ud rlk2kwun4t1
20 Jun 23
CureVac Appoints International Financial Expert Michael Brosnan to Supervisory Board
4:45pm
6-K
umf0hsz070
20 Jun 23
Current report (foreign)
4:45pm
6-K
x2e587 7b8
20 Jun 23
CureVac Announces Voting Results of General Meeting
6:03am
6-K
5enul7lc7cpq5
30 May 23
Current report (foreign)
5:20pm
6-K
kd5h4fmqxf6ttqd0yu
30 May 23
CureVac Announces Financial Results for the First Quarter of 2023 and Provides Business Update
4:20pm
6-K
0euwjpp jidxc
30 May 23
Current report (foreign)
4:15pm
6-K
4q81r8xybp248222
19 May 23
CureVac Announces Developments in Patent Litigation with Pfizer/BioNTech
4:11pm
6-K
2c4vc91aneieu
25 Apr 23
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2022 and Provides Business Update
4:22pm
6-K
0vqxpkr4427jzq
31 Mar 23
Voting results – Overview
4:08pm
6-K
e9c18mh
29 Mar 23
CureVac Announces Voting Results of Extraordinary General Meeting
4:05pm
6-K
34rc8
27 Feb 23
Current report (foreign)
4:05pm
6-K
umfz288ucrp
10 Feb 23
CureVac Announces Closing of $250 million Follow-on Public Offering of Common Shares
4:26pm
424B5
23e u3oq5
9 Feb 23
Prospectus supplement for primary offering
3:45pm
6-K
gtqn 0en1jh
7 Feb 23
CureVac Announces Pricing of Upsized Public Offering of Common Shares
8:39pm
424B4
juk8w
6 Feb 23
Prospectus supplement with pricing info
5:17pm